������ýMV

HBM+ is excited to share the third annual Drug Trends and Strategic Insights report, which highlights the drug claims and utilization data we administer on behalf of our partners. This year’s report provides the updates you are accustomed to seeing on trends tied to specialty drugs, biologics and biosimilars, as well as the impacts of new, costlier, chronic disease therapies. The report also builds upon last year’s update related to the growing use of digital pharmacy services.

As COVID-19 still poses a challenge, especially with new and emerging variants of concern, we have introduced a section on the COVID-19-related therapies being introduced to combat the virus. Shifting to future trends and the pipeline of new drug therapies, an addition to this year’s report is a deep dive on three drug classes that are seeing significant growth in terms of claimants and costs: diabetes, obesity, and cystic fibrosis.